louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03066401: Respiratory Variations for Assessing Blood Withdrawal 2
Official title: Respiratory Variations in Diameters of the Inferior Vena Cava and the Internal Jugular Vein to Assess Blood Withdrawal in Patients With Dysmetabolic Hyperferritinemia
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Dysmetabolic Syndrome
Hyperferritinemia
Obese
Keywords: hyperferritinemia
dysmetabolic hyperferritinemia
obese
blood withdrawal
respiratory variations
inferior vena cava
internal jugular vein
ultrasound
ultrasonography
echography
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2017-02-28
Enrollment: 5
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese patients with dysmetabolic hyperferritinemia

Brief summary: OBJECTIVES: To investigate whether respiratory variations of the inferior vena cava (ΔIVC) and internal jugular vein (ΔIJV) diameters during standardized breathing (ΔIVCST and ΔIJVST) increase after a therapeutic bleeding in spontaneously breathing and obese patients with dysmetabolic hyperferricemia.

DESIGN: Prospective, monocentric study in the EFS Nord-de-France blood center.

PATIENTS: Obese patients with dysmetabolic hyperferricemia undergoing a therapeutic bleeding.

INTERVENTIONS: The investigators performed ultrasound measures and collected clinical parameters before and after a therapeutic bleeding, during a standardized respiratory maneuver.

MAIN OUTCOME AND MEASURES: The primary endpoint was the ΔIVCST change induced by a 300 to 500ml therapeutic bleeding. The investigators measured the minimal and maximal IVC and IJV diameters during a standardized respiratory maneuver. ΔIVCST and ΔIJVST were calculated as follows: \[(maximal diameter - minimal diameter)/maximal diameter\].100.


Eligibility criteria: Inclusion Criteria:

* adult patients of \> or equal 18 years
* dysmetabolic hyperferritinemia
* undergoing a therapeutic blood withdrawal
* health insured
* obese (body mass index \> or equal 30Kg/m²)

Exclusion Criteria:

* pregnancy
* transthoracic echogenicity unsuitable for measuring the inferior vena cava diameters
* clinical signs of active exhalation

Primary outcomes:
measure: blood withdrawal-induced changes in the respiratory variations of the inferior vena cava during a standardized respiratory maneuver (ΔIVCST)
timeFrame: during a standardized respiratory maneuver, an average 1 hour maximum
Secondary outcomes:
measure: blood withdrawal-induced changes in the respiratory variations of the internal jugular vein during a standardized respiratory maneuver (ΔIJVST)
timeFrame: during a standardized respiratory maneuver, an average 1 hour maximum
Other outcomes:
Locations:
city: Lille
country: France
facility: Hôpital Roger Salengro, CHRU de Lille
Study officials:
affiliation: University Hospital, Lille
name: Sébastien Preau, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01636401: Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Official title: Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: COPD
Lead sponsor: Daewoong Pharmaceutical Co. LTD.
Sponsor class: INDUSTRY
First posted: 2012-07-10
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: The purpose of this study was to observe the Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD).


Eligibility criteria: Inclusion Criteria:

* A diagnosis of stable moderate to severe COPD as defined by GOLD (the Global Initiative for Chronic Obstructive Lung Disease) guidelines(http://www.goldcopd.org); a postbronchodilator FEV1/forced vital capacity \[FVC\] ratio \< 70% and FEV1 ≥ 30% to \<80% of the predicted value.
* Current or former cigarette smokers with a smoking history of at least 10 pack-years.

Exclusion Criteria:

* History or current diagnosis of asthma
* Patients who have been hospitalized for an acute COPD exacerbation within 3 months prior to Visit 1
* Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks before Visit 1.
* Patients with any clinically significant respiratory conditions other than COPD

Primary outcomes:
measure: Change from baseline to Week 12 in morning predose (trough) FEV1
timeFrame: Week 12
Secondary outcomes:
measure: Change from baseline to Week 12 in peak FEV1
timeFrame: Week 12
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
References:
citation: Lee SH, Lee J, Yoo KH, Uh ST, Park MJ, Lee SY, Kim JY, Kim DK, Kim SJ, Lee KH, Yoo CG. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population. Respirology. 2015 Nov;20(8):1222-8. doi: 10.1111/resp.12641. Epub 2015 Sep 15.
Clinical trial NCT00651001: Metabolic Syndrome and Leptin Level Associated With Fructose Consumption in Spain
Official title: Prevalence of Cardiovascular Risk Factors in Minorca - Spain
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Keywords: fructose
leptin
metabolic syndrome
blood pressure
inflammation
Relationship of fructose intake to leptin levels
Relationship of fructose to metabolic syndrome
Relationship of fructose to inflammation parameters
Relationship of fructose to blood pressure
Lead sponsor: Hospital Mateo Orfila
Sponsor class: OTHER
First posted: 2008-04-02
Enrollment: 800
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 800 Adults, age 18 to 70

Brief summary: A Food Frequency Questionnaire (FFQ), will be provided to 800 adults to assess overall fructose intake and this will be related to a number of features related to the metabolic syndrome, including serum leptin, characteristic features of metabolic syndrome (body mass index, waist circumference, plasma lipids, blood pressure, HOMA index,fasting glucose and fasting insulin levels) and other as: CRP, fibrinogen, homocysteine and uric acid.


Eligibility criteria: Inclusion Criteria:

* Adults, 18-70 years of age

Exclusion Criteria:

* Diabetes
* Kidney Failure
* Heart Failure
* Cancer

Primary outcomes:
measure: Serum leptin levels as it relates to fructose intake
timeFrame: Epidemiological association
Secondary outcomes:
measure: Relationship of metabolic syndrome features with fructose intake. This includes measuring all 5 components of metabolic syndrome, assessing insulin resistance by HOMA, and measuring some markers of inflammation (CRP, fibrinogen, homocysteine)
timeFrame: Epidemiological
Other outcomes:
Locations:
city: Menorca
country: Spain
facility: Renal Unit of Mateo Orfila Hospital, Balearic Islands - Spain
state: Balearic Islands
Study officials:
References:
Clinical trial NCT01225601: Prospective Evaluation of Adult Pulmonary Langerhans Cell Histiocytosis
Official title: Epidemiology of Adult Adult Pulmonary Langerhans Cell Histiocytosis - A Multicenter Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Adult Pulmonary Langerhans Cell Histiocytosis
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2010-10-21
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult Pulmonary Langerhans cell histiocytosis

Brief summary: Study objectives:

* To estimate the incidence of pulmonary deterioration in adult pulmonary Langerhans cell histiocytosis
* To assess the impact of tobacco discontinuation
* Study Design Multicentric prospective cohort study
* Main endpoint: Pulmonary deterioration
* Sample size : 40 patients

Detailed description: Study objectives To estimate the incidence of pulmonary deterioration in adult pulmonary Langerhans cell histiocytosis To assess the impact of tobacco discontinuation Study Design Multicentric prospective cohort study Main endpoint: Pulmonary deterioration Sample size : 40 patients

Eligibility criteria: Inclusion Criteria:

* Pulmonary Langerhans cell histiocytosis diagnosed within the past 48 months

Exclusion Criteria:

* Age \< 18
* Deep pulmonary dysfunction (CPT\< 60%, FEV1\< 30%, DLCO\< 30%, partial pressure of oxygen in arterial blood (PaO2)\< 60mmHg)
* No informed consent or consent withdrawal

Primary outcomes:
measure: Pulmonary deterioration
timeFrame: 2 years
Secondary outcomes:
measure: Evolution of pulmonary volumes (FEV1)
timeFrame: 6 months
measure: Evolution of pulmonary lesions in High Resolution Computed Tomography (HRCT)
timeFrame: 6 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital Saint Louis
Study officials:
affiliation: Assistance Publique - Hôpitaux de Paris
name: Abdellatif TAZI, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tazi A, de Margerie C, Naccache JM, Fry S, Dominique S, Jouneau S, Lorillon G, Bugnet E, Chiron R, Wallaert B, Valeyre D, Chevret S. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis. 2015 Mar 14;10:30. doi: 10.1186/s13023-015-0249-2.
citation: Tazi A, de Margerie-Mellon C, Vercellino L, Naccache JM, Fry S, Dominique S, Jouneau S, Lorillon G, Bugnet E, Chiron R, Wallaert B, Valeyre D, Chevret S. Extrathoracic investigation in adult patients with isolated pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis. 2016 Feb 2;11:11. doi: 10.1186/s13023-016-0387-1.
Clinical trial NCT02666001: A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone
Official title: A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Buprenorphine/Naloxone and BMS-663068
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Infection, Human Immunodeficiency Virus
Lead sponsor: ViiV Healthcare
Sponsor class: INDUSTRY
Collaborators: name: GlaxoSmithKline
First posted: 2016-01-28
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The study is being conducted to assess the effect of multiple doses of BMS-663068 on the exposure of methadone in subjects on a stable dose of methadone, and the exposure of buprenorphine and norbuprenorphine in subjects on a stable dose of buprenorphine and norbuprenorphine.


Eligibility criteria: Inclusion Criteria:

1. Signed Informed Consent
2. Target population: Subjects on methadone maintenance therapy (for inclusion in Part 1) or buprenorphine and norbuprenorphine maintenance therapy (for inclusion in Part 2), who have been reliably participating in an oral methadone or buprenorphine and norbuprenorphine program and who are on a stable dose for at least 30 days prior to study screening
3. Male and Female Subjects with body mass index of 18 to 34 kg/m2, inclusive
4. Women of child bearing potential (WOCBP) with negative serum or urine pregnancy test and must not be breastfeeding
5. Men and WOCBP must agree to follow instructions for contraception

Exclusion Criteria:

1. History of any chronic or acute illness, gastrointestinal disease, smoking and alcohol abuse
2. Any Gastrointestinal (GI) surgery within 4 weeks of study drug administration that could affect its absorption
3. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations beyond what is consistent with the target population.
4. History of allergy to any drugs, BMS-663068, HIV attachment inhibitors, or related compounds

Primary outcomes:
measure: Cmax for Methadone (Part 1) and buprenorphine and norbuprenorphine (Part 2)
timeFrame: Days 1 to 10
measure: AUC(TAU) for Methadone (Part 1) and buprenorphine and norbuprenorphine (Part 2)
timeFrame: Days 1 to 10
Secondary outcomes:
measure: Incidence of Adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.
timeFrame: For AEs, Days 1 to 10; for SAEs, Screening, Days 1 to 10 and up to 30 days post discontinuation of dosing
Other outcomes:
Locations:
city: Orlando
country: United States
facility: GSK Investigational Site
state: Florida
city: Overland Park
country: United States
facility: GSK Investigational Site
state: Kansas
Study officials:
affiliation: ViiV Healthcare
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT01774201: Respiratory Function and Walking Capacity in Multiple Sclerosis
Official title: Respiratory Function and Walking Capacity in Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Respiratory; Disorder, Functional, Impaired
Difficulty Walking
Keywords: Multiple sclerosis
Self-assessment
Physical endurance
Respiratory function
Fatigue
Lead sponsor: Region Örebro County
Sponsor class: OTHER
Collaborators: name: Örebro County Council
First posted: 2013-01-23
Enrollment: 50
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Multiple sclerosis (MS) is a chronic progressive neurological disease. Respiratory dysfunction due to weakness in the respiratory musculature has been described in MS. This leads to increased morbidity and mortality in late stages of the disease. It is possible that respiratory dysfunction influence physical fitness in earlier stages as well. Walking disability and fatigue causes significant impact on health in patients with MS, even in earlier stages.

The hypothesis is that there is a relationship between respiratory function, walking capacity and fatigue and that daily deep breathing exercise during two months will improve respiratory function, walking capacity and fatigue.

Detailed description: Presented above.

Eligibility criteria: Inclusion Criteria:

* Inhabitant in Orebro county, Sweden, that are diagnosed with MS according to the revised McDonald criteria and registered in the Swedish MS-registry with EDSS (Expanded disability status scale) score in the interval ≥ 3.0 - ≤ 7.0.
* Participants must understand verbal and written information and must be relapse free ≥ 3 months prior to inclusion.

Exclusion Criteria:

* Patients with diseases that may have influence on walking ability and respiratory function (other than MS). Such conditions include heart and lung diseases, orthopedic disorders, patients recently subjected to surgery, and non-MS related neurological dysfunction.

Primary outcomes:
measure: Respiratory muscle strength
timeFrame: Two months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Department of Physiotherapy, Örebro University Hospital
name: Elisabeth Westerdahl, Phd
role: PRINCIPAL_INVESTIGATOR
References:
citation: Westerdahl E, Wittrin A, Kanahols M, Gunnarsson M, Nilsagard Y. Deep breathing exercises with positive expiratory pressure in patients with multiple sclerosis - a randomized controlled trial. Clin Respir J. 2016 Nov;10(6):698-706. doi: 10.1111/crj.12272. Epub 2015 Mar 2.
citation: Nilsagard Y, Westerdahl E, Wittrin A, Gunnarsson M. Walking Distance as a Predictor of Falls in People With Multiple Sclerosis. Physiother Res Int. 2016 Jun;21(2):102-8. doi: 10.1002/pri.1625. Epub 2015 Mar 17.
Clinical trial NCT04090801: Comparison of Topical Minoxidil 5% in Ethanol Plus Propylene Glycol Versus Minoxidil 5% in Ethanol Alone in Treatment of Women With Female Pattern Hair Loss
Official title: Minoxidil in Treatment of Androgenetic Alopecia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Female Pattern Hair Loss
Keywords: Female pattern hair loss
Minoxidil.
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2019-09-16
Enrollment: 60
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This study will be to compare the efficacy of topical minoxidil 5% solution in ethanol plus 5% propylene glycol (PG), as a vehicle, versus 5% minoxidil in ethanol alone in treatment of women with FPHL.
Primary purpose: TREATMENT

Brief summary: The study will be included 60 women with FPHL. The diagnosis of FPHL will be established by clinical (Ludwig classification) and trichoscopic evaluation of frontal and occipital regions of the scalp.

Detailed description: Enrolled women will be randomly assigned into 3 treatment groups: group A will apply topical minoxidil 5% in 90% ethanol and 5% propylene glycol, group B will apply topical minoxidil 5% in pure ethanol alone and group C will apply pure ethanol (placebo) twice daily.

The treatment will be continued for six months with regular visits at 3 months intervals.

The medications will be provided in bottles which were identical in shape and color, and were coded by a third party.

Both patients and investigator will be blinded to the medication. Disclosure of the codes will be done, by a third party, at the end of the study.

Eligibility criteria: Inclusion Criteria:

* FPHL

Exclusion Criteria:

* No

Primary outcomes:
measure: Ludwig scale grading system
timeFrame: 0-6 months
measure: Trichoscopic examination of the hairs at frontal and occipital regions of the scalp.
timeFrame: 0-6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Faculty of Medicine, Sohag University, Egypt.
name: Mohammed Abu El-Hamd, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03243201: Silver Nanoparticle Investigation for Treating Chronic Sinusitis
Official title: The Efficacy and Safety of Intranasal Colloidal Silver Nanoparticles for Chronic Rhinosinusitis: A Proof-Of-Concept, Double-Blinded, Placebo-Controlled, Randomized Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Chronic Rhinosinusitis (Diagnosis)
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2017-08-08
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chronic rhinosinusitis is a highly prevalent disease resulting in high economic burden. Effective therapeutic options are needed. Rhinosinusitis-related biofilms are a likely contributor to recalcitrant disease. Emerging evidence shows that colloidal silver nanoparticles may be effective for reducing biofilms. The investigators intend to perform a randomized, double-blinded, placebo-controlled clinical trial to evaluate the effectiveness and safety of intranasal colloidal silver nanoparticles in adult patients with chronic rhinosinusitis. The investigators hypothesize that compared to placebo, treatment with intranasal colloidal silver for chronic rhinosinusitis will lead to a significant improvement in symptom scores and will not be associated with increased rate of adverse effects.


Eligibility criteria: Inclusion Criteria:

Twelve (12) weeks or longer of two or more of the following signs and symptom consistent with chronic rhinosinusitis (CRS):

* mucopurulent drainage (anterior, posterior, or both), nasal obstruction (congestion), facial pain-pressure-fullness, or decreased sense of smell

AND inflammation is documented by one or more of the following findings:

* purulent (not clear) mucus or edema in the middle meatus or ethmoid region
* polyps in nasal cavity or the middle meatus
* and/or radiographic imaging showing inflammation of the paranasal sinuses

Exclusion Criteria:

* Unable to speak English
* History of nasal or sinus surgery within past 6 weeks
* History of comorbid ciliary dyskinesia, cystic fibrosis or any other mucociliary condition
* Dependence on prolonged corticosteroid therapy for comorbid condition
* History of renal impairment
* History of cerebrospinal fluid leak

Primary outcomes:
measure: Sino-Nasal Outcome Test (SNOT-22)
timeFrame: Four weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06450301: Senescent Endometrial Cells in Patients with Thin Endometrial Lining
Official title: Is Thin Endometrial Lining Associated with Senescent Endometrial Cells
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Asherman's Syndrome
Thin Endometrial Lining
Cell Senescence
Lead sponsor: Trio Fertility
Sponsor class: OTHER
First posted: 2024-06-10
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: We intend to recruit 30 patients following long-term use of oral contraceptives with known thin endometrial lining (less than 7mm, confirmed in at least two cycles and unresponsive to estrogen-induced growth). We will also recruit 20 women with Asherman's syndrome following D\&C. We will ask each woman to undergo an endometrial biopsy as part of the study. As a control group, we will recruit 50 patients already scheduled to undergo an endometrial biopsy for infertility management (EMMA testing, endometrial scratching for IVF cycles). Endometrial biopsies are standard procedures during infertility investigations. In some cases, we may be able to access archived endometrial samples from women in the control group who agree to participate and who have already had an endometrial biopsy.

Brief summary: The goal of this observational study is to determine if thin endometrial lining that is unresponsive to estrogen might be associated with the presence of senescent cells in patients following long-term use of oral contraceptives. The main question it aims to answer is:

Are there any senescent cells present in thin endometrial lining?

During the luteal phase of the cycle, participants will will undergo:

* Gynecologic US to measure the endometrial lining thickness and pattern.
* Endometrial biopsy with Pipelle catheter

Detailed description: The investigators hypothesized that senescent cells in the endometrium may be the cause of the failure of thin endometrium to respond to normal growth stimuli such as estrogen.

The outcome that research team anticipate to measure is the percentage of senescent cells in the endometrial biopsies of women with thin endometrium compared to the control group biopsies.

Eligibility criteria: Inclusion Criteria:

* Age 18-39
* BMI - up to 35
* Thin endometrium after OCP use
* Asherman's syndrome
* Women already undergoing endometrial biopsy for infertility testing (eg. EMMA testing)
* Women with archived endometrial biopsy samples

Exclusion Criteria:

* Women with systemic disease (Rheumatic disease, DM)
* Women with coagulopathies
* Women with active pelvic inflammatory process
* Uterine anomalies
* Pregnant women
* Any hormonal contraception use or IUD

Primary outcomes:
measure: Senescent cells presence
timeFrame: Through study completion, an average of 3 years.
Secondary outcomes:
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Trio Fertility
state: Ontario
Study officials:
References: